We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
EquiTech has announced further details of its Phase II clinical trial of ZAG-1701,
its novel reformulated ibuprofen caplet, following a review of the results of
the clinical trial conducted by Analgesic Development of New York.
Miravant Medical Technologies, a pharmaceutical development company specializing
in PhotoPoint photodynamic therapy, plans to conduct a confirmatory Phase III
clinical trial for Photrex (rostaporfin, formerly known as SnET2) at investigational
sites in Central and Eastern Europe and the UK.
The European Commission (EC) granted Maxim Pharmaceuticals' Ceplene (histamine
dihydrochloride) orphan-drug designation for the treatment of acute myeloid
leukemia patients following adoption of a positive opinion by the Committee
for Orphan Medicinal Products of the European Medicines Agency.
Researchers from Boston University School of Medicine, University of Texas Southwestern
Medical Center at Dallas and Sequenom have discovered a genetic variation that
is the strongest known risk factor associated for age-related macular degeneration
(AMD).
Data presented at the American College of Cardiology Annual Scientific Sessions
showed that glycoprotein (GP) IIb-IIIa inhibitors and Integrilin were pivotal
components of the optimal treatment strategy for reducing risk of heart attack
and death in patients undergoing percutaneous coronary intervention (PCI).
Results of two major clinical trials showed that the antiplatelet agent clopidogrel,
given on top of standard therapy, provided significant benefits to patients
with acute ST-segment elevation myocardial infarction (STEMI), a certain kind
of heart attack.
Immtech International has said that test results from patients enrolled in the
Phase IIb clinical trial using DB289 for the oral treatment of Trypanosomiasis
confirm that all patients tested remained clear of the African sleeping sickness
parasite three months after concluding treatment.
Oscient Pharmaceuticals has completed enrollment in its pivotal Phase III clinical
trial comparing a five-day treatment of Factive (gemifloxacin mesylate) tablets
to the FDA-approved seven-day course of therapy for the potential treatment
of community-acquired pneumonia of mild-to-moderate severity.